Guy Breitenbucher

Guy Breitenbucher has extensive experience in the field of drug discovery and medicinal chemistry. Guy has held various leadership roles in both biotech and pharmaceutical companies.

From 2010 to 2018, Breitenbucher served as the Senior Director of Discovery Chemistry at Dart Neurosciences, where they managed a team of scientists and oversaw all aspects of drug discovery chemistry. Guy was responsible for target discovery and validation, pre-clinical candidate selection, and decision-making for drug discovery projects. Guy also collaborated with other departments such as biology, pharmacology, and toxicology.

Prior to their role at Dart Neurosciences, Breitenbucher worked at Johnson & Johnson for 11 years. During their tenure, they led the Hit-to-lead and Pain Chemistry departments at Janssen's San Diego research facility. Guy supervised multiple programs that entered clinical development, focusing on various therapeutic indications including immunology, metabolic disorders, pain, and CNS.

In addition, Breitenbucher has experience as a Scientist at Axys Pharmaceuticals and Bristol Myers Squibb.

More recently, they have worked as a Consultant at Breiten Consulting since 2018. Guy specializes in drug discovery project management, medicinal chemistry, intellectual property, and business development. Guy provides external drug discovery project management expertise for biotech and pharmaceutical companies, with a focus on chemistry, DMPK, and project management.

Breitenbucher's most recent roles include being the Vice President of Chemistry at Convelo Therapeutics from 2018 to 2020, where they managed the company's project collaborations with Genentech. Guy played a key role in compound design and synthesis, as well as collaboration with Genentech scientists and management. Guy also served as the Vice President of Chemistry at Libra Therapeutics from 2020 to 2022, where they managed all chemistry operations and led projects focused on small molecule treatments for ALS and other neurodegenerative diseases.

Currently, Breitenbucher is the VP Chemistry at Annexon Biosciences, a position they started in 2022. The details about their role at Annexon Biosciences are not provided.

In summary, Guy Breitenbucher has a strong background in drug discovery and medicinal chemistry with leadership experience in both biotech and pharmaceutical companies. Their expertise includes project management, compound design, collaboration with external partners, and strategic decision-making.

Guy Breitenbucher completed their Ph.D. in Chemistry from the University of California, Riverside, from 1989 to 1993. Guy then pursued a postdoctoral position at the University of California, Berkeley, from 1993 to 1995 to further their knowledge and expertise in Chemistry.